Catabasis Pharmaceuticals

Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Once-struggling, Catabasis Pharmaceuticals Inc (NASDAQ: CATB) is looking to hit the reset button with a new name and focus. Catabasis has been dragging for several years, weighed down mainly by the failure of the edasalonexent program in Duchenne muscular dystrophy.

Catabasis Renames As Astria Therapeutics With New Disease Focus

BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE), today announced its new name, Astria Therapeutics, Inc. (“Astria” or the “Company”). The name Astria originates from the Greek word for star, reflecting the Company's commitment to having patients serve as guiding stars. Astria's mission is to bring hope with life-changing therapies to patients and families. Astria expects to

Catabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics, Highlighting New Company Focus

Catabasis Pharmaceuticals Inc (NASDAQ: CATB) deployed a reverse stock split of its shares of common stock at a ratio of 1-for-6. These are the details.

Catabasis Pharmaceuticals Shares: 1-For-6 Split Goes Into Effect

BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides a Corporate Update

Catabasis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides a Corporate Update

BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals To Present At 2021 Wedbush PacGrow Healthcare Conference

Catabasis Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference

BOSTON--(BUSINESS WIRE)--Catabasis will present information on its lead program QLS-215 at the Ladenburg Thalmann 2021 Healthcare Conference.

Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference

After edasalonexent's failure last year, Catabasis Pharmaceuticals pivoted to the HAE market through the acquisition of Quellis Biosciences.

Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition

Kindred Biosciences

Aprea Therapeutics

Inhibikase Therapeutics

Kindred Biosciences, Inc. (NASDAQ: KIN), Aprea Therapeutics, Inc. (NASDAQ: APRE), Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) and Inhibikase Therapeutics, Inc. (NASDAQ: IKT) are among the biggest biopharma movers on Wednesday. Kindred Flies On Buyout: Kindred announced an agreement to be bought by Elanco Animal Health Incorporated (NYSE: ELAN) for $9.25 per share, or approximately $440 million.

Why Kindred Biosciences, Aprea, Catabasis And Inhibikase Are Moving Today

The stock price of Catabasis Pharmaceuticals Inc (NASDAQ: CATB) increased by over 40% pre-market. This is why it happened.

CATB Stock Price Increases Over 40% Pre-Market: Why It Happened

BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences

Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides a Corporate Update

Catabasis Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides a Corporate Update

Agile Therapeutics

Aqua Metals

Checkpoint Therapeutics

Hepion Pharmaceuticals Inc

InflaRx

Limelight Networks

Investors in penny stocks know the prices of many have crashed. But these seven stocks may have room to run higher.

7 Penny Stocks That May Have Room to Run Higher

BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update

Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update

Oracle

Tesla

American Electric Power Company

Biohaven Pharmaceutical Hld

Esperion Therapeutics

Keurig Dr Pepper Inc

Restaurant Brands

Werner Enterprises

With the trading day halfway over, the broad markets were making yet another strong push.

AEP, Oracle, Tesla and More Thursday Afternoon Analyst Calls

Catabasis Pharma (CATB) stock is soaring higher on Friday after announcing its acquisition of Quellis Biosciences and a PIPE. The post CATB Stock: Why Catabasis Pharma Stock Is Skyrocketing Today appeared first on InvestorPlace.

CATB Stock: Why Catabasis Pharma Stock Is Skyrocketing Today

Investors need to pay close attention to Catabasis (CATB) stock based on the movements in the options market lately.

Implied Volatility Surging for Catabasis (CATB) Stock Options

Catabasis Pharmaceuticals (CATB) stock is taking off on Wednesday despite a lack of news from the biopharmaceutical company. The post Catabasis Pharmaceuticals: 9 Things for Potential CATB Stock Investors to Know appeared first on InvestorPlace.

Catabasis Pharmaceuticals: 9 Things for Potential CATB Stock Investors to Know

Catabasis Pharmaceuticals (CATB) news for Tuesday includes incredibly poor results from a clinical trial hammering CATB stock hard. The post Catabasis Pharmaceuticals News: Why CATB Stock Is Plummeting 69% Today appeared first on InvestorPlace.

Catabasis Pharmaceuticals News: Why CATB Stock Is Plummeting 69% Today

Catabasis is approaching its highly anticipated Q4 readout for their Phase III PolarisDMD study. If the data is acceptable, Catabasis expects to file an NDA in 2021.

Catabasis Pharmaceuticals: Accumulating Ahead Of Edasalonexent's Top-Line Results

Are Options Traders Betting on a Big Move in Catabasis (CATB) Stock?

Catabasis Pharmaceuticals (CATB) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Catabasis Pharmaceuticals (CATB) Surges: Stock Moves 8.6% Higher

Catabasis: Worth A Look Ahead Of Phase III Data

Catabasis Pharmaceuticals Inc. (CATB) CEO Jill Milne on Q4 2019 Results - Earnings Call Transcript

Catabasis (CATB) teams up with Duchenne UK to fund a phase II study of its pipeline candidate edasalonexent, now being developed to treat patients with non-ambulatory Duchenne muscular dystrophy.

Catabasis (CATB) Partners with UK-Based Charity for DMD Study

Catabasis Pharmaceuticals' (CATB) CEO Jill Milne on Q3 2019 Results - Earnings Call Transcript

News for Catabasis Pharmaceuticals Stock (CATB)